Analyst Price Targets — AVBP
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| December 10, 2025 11:42 am | — | BTIG | $45.00 | $24.91 | TheFly | ArriVent Biopharma initiated with a Buy at BTIG on firmonertinib potential |
| November 25, 2025 11:23 am | — | Truist Financial | $43.00 | $21.51 | TheFly | ArriVent Biopharma initiated with a Buy at Truist |
| July 10, 2025 9:03 am | Corinne Johnson | Goldman Sachs | $33.00 | $22.03 | TheFly | ArriVent Biopharma resumed with a Buy at Goldman Sachs |
| September 10, 2024 11:49 am | Yigal Nochomovitz | Citigroup | $36.00 | $27.93 | StreetInsider | ArriVent BioPharma (AVBP) PT Raised to $36 at Citi |
| September 10, 2024 6:38 am | Robert Burns | H.C. Wainwright | $36.00 | $28.04 | StreetInsider | ArriVent BioPharma (AVBP) PT Raised to $36 at H.C. Wainwright |
| August 16, 2024 6:39 am | Robert Burns | H.C. Wainwright | $30.00 | $23.62 | StreetInsider | ArriVent BioPharma (AVBP) PT Raised to $30 at H.C. Wainwright |
| July 22, 2024 7:05 am | Jeff Jones | Oppenheimer | $35.00 | $18.77 | StreetInsider | Oppenheimer Starts ArriVent BioPharma (AVBP) at Outperform |
Latest News for AVBP
Insight into Leon Cooperman (Trades, Portfolio)'s Fourth Quarter 2025 13F Filing Leon Cooperman (Trades, Portfolio) recently submitted the 13F filing for the f
/PRNewswire/ -- USANewsGroup.com News Commentary - The FDA isn't just approving drugs; they are completely reshaping the landscape. In 2025 alone, the agency
ArriVent BioPharma (AVBP) is a cautious BUY, driven by furmonertinib's late-stage potential in uncommon EGFR-mutant NSCLC and a conservative valuation approach. AVBP's strategy targets niche EGFR mutations—exon 20 insertions, PACC, and others—where competition is less entrenched and regulatory pathways are more navigable. Furmonertinib demonstrates robust efficacy, CNS penetration, and tolerability in early trials,…
ArriVent BioPharma is rated a Strong Buy, driven by Firmonertinib's near-term clinical catalysts and significant de-risking from Shanghai Allist Pharmaceuticals commercialization. Firmonertinib has continued to deliver encouraging efficacy with a tolerable safety profile across treated patients. Under conservative assumptions, there is an asymmetric valuation setup.
NEWTOWN SQUARE, Pa., Dec. 22, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced that the first patient has been dosed in the global pivotal Phase 3 ALPACCA study evaluating firmonertinib monotherapy for first-line treatment of EGFR PACC mutant…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for AVBP.
U.S. House Trading
No House trades found for AVBP.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.